Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trialMarco Colleoni, Joanna Vermeij, Stefan Aebi et al.|The Lancet Oncology|2017Cited by 122
Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.Jean‐François Baurain, Laurette Renard, Daniel Devriendt et al.|Journal of Clinical Oncology|2010Cited by 2